Abstract
What's new in the management of chronic lymphocytic leukemia? 2008 ASH Review (New York Medical College, January 31, 2009)
Highlights
2095 updated results of a phase II study of cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) in 48 previously untreated patients with high-risk features [9]
Grade 3–4 neutropenia and thrombocytopenia were observed in 71% and 42% of patients, respectively, and 6% and 27% of patients developed major and minor infections, respectively
Grade 3–4 myelosuppression and tumor flare were observed in 26% and 44% of patients, respectively
Summary
2095 updated results of a phase II study of cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) in 48 previously untreated patients with high-risk features [9]. Abstract 325 presented results of the German CLL Study Group (GCLLSG) CLL8 study randomizing 817 previously untreated patients to fludarabine and cyclophosphamide (FC) or fludarabine, cyclophosphamide and rituximab (FCR) [6]. Abstract 327 randomized 184 patients (80% previously untreated, 20% relapsed) to PCR or FCR, using the MSKCC PCR regimen (pentostatin dose 4 mg/m2) and the Johns Hopkins FCR regimen (fludarabine 20 mg/m2 days 1–5, cyclophosphamide 600 mg/m2 day 1).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have